The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

1. González-Larriba, J.L.
2. Maroto, P.
3. Durán, I.
4. Lambea, J.
5. Flores, L.
6. Castellano, D.
7. Anido, U.
8. Basterrechea, L.
9. Casanovas, O.
10. Chirivella, I.
11. Climent, M.Á.
12. Dur, I.
13. Gallardo, E.
14. Garc, R.
15. Guix, M.
16. Laínez, N.
17. Marino, A.M.
18. Montesa, Á.
19. Pinto, A.
20. Puente, J.
21. Romero, G.R.
22. Suárez, C.
23. Virizuela, J.A.